Daniel Kraft, MD - among the nation’s most prolific, multi-dimensional, and “applied healthcare" futurists - is a Stanford- and Harvard-trained physician-scientist with over 20 years of experience in clinical practice, biomedical research, and healthcare innovation. He is a serial entrepreneur, educator, inventor/developer of medical devices, drug therapies, and telecommunications systems.

Currently, Daniel is the Founder and CEO of IntelliMedicine, which focuses on enabling connected, data-driven, and integrated personalized medicine. He also chairs the Medicine Track for Singularity University and is Executive Director of its FutureMed Program, which educates, informs, and prepares physicians and senior healthcare executives to understand and recognize the opportunities and disruptive influences of exponentially growing technologies within medicine and healthcare, and to understand how many rapidly developing and converging fields affect the future of clinical practice and the biomedical industry. read more

Debra Reisenthel had led Novasys Medical, a women’s health company, since its inception, in 2001.  Along the way, she raised $90 million in venture capital to see the company’s flagship product, the Renessa® System, through product development, animal studies, human clinical trials, FDA-approval, market acceptance, and widespread reimbursement.  In a market with huge challenges, few visionaries remain a company’s chief executive throughout the entire progression, from idea to commercialization.

Renessa was named the 2009 Most Promising New Product, selected by industry CEOs, at the Phoenix Medical Device and Diagnostic Conference. Also since 2009, Renessa has received several positive insurance coverage decisions, including approvals for nationwide coverage from Aetna, a positive Blue Shield of California Technology Assessment (CTAF), and coverage approvals from seven of the ten Medicare regions - enabling Medicare to cover Renessa for over 75% of insured women nationwide. read more